Ghassan El-Haddad, MD

Dr. Ghassan El-Haddad is an Interventional and Nuclear Oncologist, and the Medical Director of the Radionuclide Therapy Program at H. Lee Moffitt Cancer Center and Research Institute (MCC). He is a Senior Member in the Department of Diagnostic Imaging and Interventional Radiology at MCC, and a Professor of Radiology and Oncologic Sciences at the University of South Florida in Tampa, FL. He received his medical degree from the Lebanese University in Beirut, Lebanon then completed a residency in Nuclear Medicine as well as a fellowship in Nuclear Oncology at the Hospital of the University of Pennsylvania (HUP) in Philadelphia, PA. Following 2 years of practice at the PET center of the Biomedical Research Foundation of Northwest Louisiana, he completed a Radiology Residency at St Vincent’s Medical Center in Bridgeport, CT, followed by a fellowship in Interventional radiology at HUP. He is board certified by the American Board of Nuclear Medicine and the American Board of Radiology. He is an active member of multiple medical societies, served for 6 years on the Board of Directors of the American Board of Nuclear Medicine and currently serves on the Board of Directors of the North American Neuroendocrine Tumor Society. He is an investigator on several phase I/II, and phase III multicenter randomized clinical trials on targeted radionuclide therapy. He was one of the key researchers on studies that led to FDA approval of Lu-177 DOTATATE for the treatment of metastatic neuroendocrine tumors and Lu-177 PSMA-617 for the treatment of metastatic castration resistant prostate cancer. His research encompasses the development of new radionuclide therapies for various tumor types and expansion of Interventional Nuclear Oncology which focuses on personalized image-guided delivery of radioactive agents and devices.